Thrombin

Bivalirudin acetate is a thrombin inhibitor, a peptide-based anticoagulant, used for research on acute coronary syndrome.

Dabigatran etexilate (BIBR 1048) is a thrombin inhibitor, which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation.

Dabigatran prevents blood clots, inhibiting NQO2 and thrombin with IC50 0.8 μM.

YD-3 is a PAR4 antagonist that significantly inhibits thrombin-induced platelet aggregation in rabbits (IC(50)=28.3 microM). In addition, YD-3 suppresses thrombin-induced proliferation of vascular smooth muscle cells (VSMCs) and reduces neointimal thickening after balloon injury. Through Ras- and ERK1/2-mediated signaling pathways, YD-3 impedes thrombin-driven VSMC proliferation. When analyzed with Western blot, YD-3 primarily inhibits thrombin-induced expression of vascular endothelial growth factor receptor 2 (Flk-1) without affecting extracellular signal-regulated kinase 1/2 phosphorylation. YD-3 could potentially have value in elucidating the pathophysiology of thrombin-induced angiogenesis.

PPACK Dihydrochloride is a selective thrombin inhibitor used in anticoagulation and serine protease studies.

Idarucizumab, a humanized monoclonal antibody fragment, serves as the first reversal agent for direct oral anticoagulants (DOACs).

Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide with greater thrombin affinity than Hirugen, exhibiting a dissociation constant (K

Hirullin P18 is a potent thrombin inhibitor with anticoagulant properties [1].

TFLLRNPNDK-NH2 is a biologically active peptide and a thrombin receptor activating peptide (TRAP).

A unique collection of 343 protease and proteasome inhibitors for research in chemical genomics, and drug screening;

Thrombin receptor peptide ligand, a thrombin receptor antagonist, serves as an antithrombotic agent [1].

Thrombin inhibitor 13 (Compound 13a) acts as a covalent reversible inhibitor of thrombin (thrombin, FIIa) with an IC50 of 0.7 nM. This compound prolongs activated partial thromboplastin time (aPTT) and prothrombin time (PT), demonstrating both antithrombotic and anticoagulant properties.

Hirudin (55-65) (sulfated), a fragment of Hirudin, is a thrombin inhibitor with anticoagulant effects and blood anticoagulant properties.

H-Gly-Arg-pNA 2HCl, a peptide, binds 1,2 thrombin; colorimetric quantification at 405 nm indicates thrombin activity.

Metolazone (SR-720-22) is a quinazoline-sulfonamide derived diuretic that inhibits sodium chloride symporters.

Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets thrombin. It binds to exosite 1 of thrombin, inhibiting substrate binding without affecting its catalytic activity. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Acetyl-Hirudin (54-65) (sulfated) binds thrombin-rHCII(L444R), blocking rHCII's N-terminal/thrombin exosite I interaction, stabilizing the complex.

Knob A peptide GPRPFPAC is a fibrin knob peptide. The PEGylated form of Knob A peptide GPRPFPAC exhibits enhanced anticoagulant activity.

Hirudin (54-65) TFA, a segment of the 65-amino-acid protein Hirudin, exhibits anticoagulant properties [1].

Sulodexide is an orally administered combination of glycosaminoglycans, consisting of low molecular weight heparin (80%) and dermatan sulfate (20%). It demonstrates antithrombotic properties by interacting with antithrombin III (AT III) and heparin cofactor II (HC II), and by inhibiting thrombin formation. Additionally, sulodexide enhances profibrinolytic activity by releasing tissue plasminogen activator (tPA). It also offers endothelial protection, possesses anti-inflammatory effects, and alleviates chronic venous disease.

Fibrinogen-binding peptide mimics vitronectin site and activates platelets; thrombin turns it to fibrin.

Platelet aggregation-IN-1 (Compound 10e) acts as an inhibitor of platelet aggregation and can achieve complete (100%) inhibition of thrombin-induced platelet aggregation at a concentration of 50 μM.

Thrombin (MW 37kDa) is a trypsin-like allosteric serine protease.

Fibrinopeptide B (FPB) is produced during the cleavage of fibrinogen, by thrombin, to fibrin monomer.

Peptide that reverses the anticoagulant effect of heparin. Potently binds heparin (Kd = 36 nM in vitro).

Coagulation Factor II Protein, Rat, Recombinant (His) is expressed in HEK293 mammalian cells with His tag.

Anti-Coagulation Factor II Antibody (2P591) is a Rabbit antibody targeting Coagulation Factor II. Anti-Coagulation Factor II Antibody (2P591) can be used in WB.

Anti-Coagulation Factor II Antibody (8M286) is a Rabbit antibody targeting Coagulation Factor II. Anti-Coagulation Factor II Antibody (8M286) can be used in ELISA.

Dabigatran ethyl ester (Dabigatran (ethyl ester)) is an emerging oral anticoagulant and it also is a direct inhibitor of thrombin activity.

Coagulation Factor II Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag.

Dabigatran Etexilate Mesylate (BIBR 1048MS) is the orally active prodrug of dabigatran. Dabigatran is a reversible and selective, direct thrombin inhibitor.

MNS is a tyrosine kinases inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively.

Lusutrombopag (Mulpleta) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist for chronic liver disease (CLD) patients with

Dabigatran (BIBR 953ZW), a thrombin inhibitor, prevents thrombus formation, reducing stroke and embolism risk in nonvalvular atrial fibrillation patients.

Enoxaparin, a low-weight heparin approved by FDA for STEMI, enhances antithrombin and prevents clotting by inhibiting factors XIa, IXa, Xa, IIa.

AEBSF hydrochloride (Pefabloc SC) is an irreversible inhibitor of serine proteases, such as chymotrypsin, kallikrein, thrombin, plasmin, and trypsin.

H-D-Phe-Pip-Arg-pNA dihydrochloride (S-2238) is a sensitive and accurate thrombin detection substrate for measuring antithrombin-heparin cofactor (AT-III).

Bivalirudin (BG-8967) is a reversible inhibitor of α- and ζ-thrombin (Kis = 2.56 and 1.84 nM, respectively), enzymes that exhibit high fibrinogen-clotting

TRAP-6 (Thrombin Receptor Activator Peptide 6)(2TFA) is an agonist of protease-activated receptor 1 (PAR1).

Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention.

Argatroban Monohydrate is a specific thrombin inhibitor, which is a non-heparin anticoagulant, prevents the formation of thrombi.

Avatrombopag (YM477) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation

Cycloolivil (Isoolivil) is a natural polyphenolic compound with a significant radical scavenging activity present in olive trees.

NQ301, an antithrombotic agent, inhibits collagen-challenged rabbit platelet aggregation (IC50: 10 mg/mL).

Ximelagatran, oral direct thrombin inhibitor, transforms to active melagatran in body.

Argatroban (MCI-9038), a specific thrombin inhibitor, which is a non-heparin anticoagulant, prevents the formation of thrombi.

TPO agonist 1, Thrombopoietin (TPO) mimetic, promotes platelet/megakaryocyte production, for thrombocytopenia research.

OM-189 is a selective inhibitor of synthetic thrombin.

Efegatran sulfate (LY294468 sulfate) is a potent thrombin inhibitor used in the treatment of thrombotic disorders.

Atopaxar (E5555), a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.